ATE302002T1 - Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit - Google Patents

Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit

Info

Publication number
ATE302002T1
ATE302002T1 AT01939143T AT01939143T ATE302002T1 AT E302002 T1 ATE302002 T1 AT E302002T1 AT 01939143 T AT01939143 T AT 01939143T AT 01939143 T AT01939143 T AT 01939143T AT E302002 T1 ATE302002 T1 AT E302002T1
Authority
AT
Austria
Prior art keywords
pyrazole derivatives
treat infertility
compounds
infertility
treatment
Prior art date
Application number
AT01939143T
Other languages
English (en)
Inventor
Hitesh Shroff
Adulla P Reddy
Tayar Nabil El
Nadia Brugger
Catherine Jorand-Lebrun
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE302002T1 publication Critical patent/ATE302002T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
AT01939143T 2000-05-19 2001-05-19 Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit ATE302002T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20581400P 2000-05-19 2000-05-19
PCT/US2001/016189 WO2001087287A2 (en) 2000-05-19 2001-05-19 Use of pyrazole derivatives for treating infertility

Publications (1)

Publication Number Publication Date
ATE302002T1 true ATE302002T1 (de) 2005-09-15

Family

ID=22763739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01939143T ATE302002T1 (de) 2000-05-19 2001-05-19 Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit

Country Status (11)

Country Link
US (2) US6914069B2 (de)
EP (1) EP1282418B1 (de)
JP (1) JP4371295B2 (de)
AT (1) ATE302002T1 (de)
AU (2) AU6469401A (de)
CA (1) CA2405507A1 (de)
DE (1) DE60112742T2 (de)
ES (1) ES2243504T3 (de)
IL (1) IL152097A0 (de)
PT (1) PT1282418E (de)
WO (1) WO2001087287A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504093A (ja) * 2001-09-27 2005-02-10 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 内因性テストステロンレベルの増加方法
DK1908463T3 (da) * 2001-12-14 2011-11-28 Merck Serono Sa Fremgangsmåder til at inducere ægløsning ved anvendelse af en ikke polypeptid-CAMP-niveaumodulator
WO2004016592A1 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
EP1797072A4 (de) * 2004-09-17 2009-09-09 Exelixis Inc Pyrazolkinasemodulatoren und verwendungsverfahren
US20080167322A1 (en) * 2005-02-16 2008-07-10 Pinkerton Anthony B Substituted Pyrazoles as Modulators of Chemokine Receptors
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
JP2012516344A (ja) * 2009-01-30 2012-07-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 結晶質ｎ−｛（１ｓ）−２−アミノ−１−［（３−フルオロフェニル）メチル］エチル｝−５−クロロ−４−（４−クロロ−１−メチル−１ｈ−ピラゾール−５−イル）−２−チオフェンカルボキサミド塩酸塩
WO2011161615A1 (en) 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
WO2012003476A2 (en) * 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
CN103402515B (zh) 2010-11-09 2017-05-17 铁木医药有限公司 sGC刺激剂
WO2013046041A1 (en) * 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles for use as kinase modulators for the treatment of cancer
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
US10287251B2 (en) * 2015-06-23 2019-05-14 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative or pharmaceutically acceptable salt thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3842088A (en) * 1973-01-31 1974-10-15 Sandoz Ag Substituted naphtho pyrazoles
US5639639A (en) 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
GB8410899D0 (en) * 1984-04-27 1984-06-06 Ici Plc Phenol derivatives
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5017557A (en) 1987-07-24 1991-05-21 Industria Farmaceutica Serono S.P.A. Treatment of infertility with somatotrophin releasing factor
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4039733A1 (de) 1990-12-13 1992-06-17 Basf Ag Substituierte 5-aminopyrazole
US5869688A (en) 1994-07-20 1999-02-09 Monsanto Company Preparation of substituted 3-aryl-5-haloalkyl-pyrazoles having herbicidal activity
WO1997012884A1 (en) 1995-10-04 1997-04-10 Fmc Corporation Herbicidal 6-heterocyclic indazole derivatives
AU4945697A (en) 1996-10-09 1998-05-05 Novartis Ag Solid phase synthesis of heterocyclic compounds
CA2270469C (en) * 1996-11-19 2007-04-10 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
DE19746749C2 (de) 1997-10-23 1999-12-02 Bosch Gmbh Robert Einrichtung zum Verriegeln und Entriegeln einer Tür
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
US20030060494A1 (en) * 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
JP2005504093A (ja) * 2001-09-27 2005-02-10 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 内因性テストステロンレベルの増加方法

Also Published As

Publication number Publication date
AU6469401A (en) 2001-11-26
EP1282418A2 (de) 2003-02-12
US6914069B2 (en) 2005-07-05
US20050026985A1 (en) 2005-02-03
IL152097A0 (en) 2003-05-29
JP4371295B2 (ja) 2009-11-25
ES2243504T3 (es) 2005-12-01
AU2001264694B8 (en) 2006-05-04
WO2001087287A3 (en) 2002-05-16
AU2001264694B2 (en) 2006-01-05
WO2001087287A2 (en) 2001-11-22
US20020132844A1 (en) 2002-09-19
EP1282418B1 (de) 2005-08-17
JP2004501100A (ja) 2004-01-15
US7456201B2 (en) 2008-11-25
PT1282418E (pt) 2005-10-31
DE60112742T2 (de) 2006-02-02
CA2405507A1 (en) 2001-11-22
DE60112742D1 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE410235T1 (de) Behandlung von ballastwasser
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE50200757D1 (de) Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1282418

Country of ref document: EP

EEFA Change of the company name